Amarantus to Present LP-002 Data for Alzheimer's Blood

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Amarantus to Present LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) at Biotech Showcase 2015 Conference on January 14, 2015

SAN FRANCISCO and GENEVA, Dec. 29, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced it will be presenting a corporate overview including top-line results of its expanded LP-002 study of the Lymphocyte Proliferation Test (LymPro Test ® ) blood diagnostic for Alzheimer's disease (AD) at Biotech Showcase 2015 . Gerald E. Commissiong, President & CEO of Amarantus, will present on Wednesday, January 14, 2015 at the Parc 55 Wyndham Union Square in San Francisco, CA.

Event: Biotech Showcase 2015
Date: Wednesday, January 14, 2015
Time: 3:30 p.m. Pacific Time / 6:30 p.m. Eastern Time
Location: Parc 55 Wyndham Union Square, San Francisco, CA

Mr. Commissiong will review results of the full 140-subject LP-002 study assessing the predictive value of LymPro in patients with mild, moderate and severe AD. The results will include the dataset from the initial 72 patients showing that LymPro achieved highly statistically significant results in correctly distinguishing patients with moderate-to-severe AD from healthy controls and from the additional 68 patients in the study's extension to assess LymPro's predictive value in diagnosing early-stage AD.

A live audio webcast of the presentation may be accessed via the News and Events page of the Investor Relations section of the Amarantus corporate web site under the IR Calendar at www.amarantus.com . A webcast replay will be available approximately two hours after the presentation ends and will be archived for 30 days.

About The Biotech Showcase 2015 Conference

The Biotech Showcase 2015 Conference ( www.ebdgroup.com/bts ) takes place January 12-14, 2015 at the Parc 55 Wyndham Hotel, located at Union Square, San Francisco, California. The Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

About Alzheimer's Disease

It is estimated that over 5.4 million people in the United States suffer from Alzheimer's disease. Over 500,000 patients are diagnosed annually, with nearly one-in-eight older Americans affected by the disease. Alzheimer's is the third leading cause of death in the United States. The cost of unpaid care in the United States is estimated at over $210 billion annually. Total payments for care are estimated at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. Alzheimer's expenditures in the United States are expected to exceed $1.4 trillion by 2050.

About LymPro Test ®

The Lymphocyte Proliferation Test ( LymPro Test ® ) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes to withstand an external mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons. LymPro is unique in the use of peripheral blood lymphocytes (PBLs) as a surrogate for neuronal cell function, suggesting a common immune-based relationship between PBLs and neurons in the brain.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's disease Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test ® "), which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard ™ "). In November 2014, AMBS entered into an exclusive option agreement with Lonza Walkersville, Inc., a subsidiary of Lonza Group Ltd., to acquire Cutanogen Corporation, a subsidiary of Lonza Walkersville, to develop Engineered Skin Substitute (ESS-W), an autologous skin replacement product for the treatment of Stage 3 and Stage 4 intractable severe burns. For further information please visit www.Amarantus.com , or connect with the Company on Facebook , LinkedIn , Twitter and Google+ .

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

Investor Contact: Jenene Thomas Jenene Thomas Communications, LLC Investor Relations and Corporate Communications Advisor T: (US) 908.938.1475 E: Media Contact: Planet Communications Deanne Eagle, Media Contact T: (US) 917.837.5866

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 106

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 156

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 79

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 56

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 89

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 221

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 16

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 85

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 88

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 85

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading

Top 5 Most Recently Viewed Articles

Disney Steers Focus Towards Asia's Streaming Landscape Success

Updated Category News Views 192

Disney Enters the Competitive Asian Streaming Market Walt Disney Co (NYSE: DIS) is strategically positioning itself to dominate in the vibrant Asian streaming market. The company's latest initiative involves a significant investment in original Japanese anime, alongside the expansion of its Korean superhero franchise. With this bold move, Disney aims to establish a strong...

Continue Reading
MSSA and GSMA Unite to Expand Mobile Satellite Services

Updated Category News Views 81

Strategic Alliance of MSSA and GSMA The Mobile Satellite Services Association (MSSA) has announced an exciting new partnership with the GSMA, a leading global organization dedicated to mobile operators and the broader mobile ecosystem. This synergy aims to elevate mobile technology to new heights and transform the landscape of mobile satellite communications. Advancing...

Continue Reading
Celebrating Pioneers: 2025 XCEL Summit for Men Highlights Heroes

Updated Category News Views 259

Honoring Leadership at the 2025 XCEL Summit for Men Black Enterprise is excited to showcase the remarkable individuals receiving the prestigious XCEL Awards at the much-anticipated XCEL Summit for Men. This year's celebration promises to be a hallmark event, scheduled for mid-October at the Hyatt Regency Grand Cypress in Orlando. Attendees can expect a magnificent...

Continue Reading
Innovative Trial Launches to Combat Pediatric Leukemia Worldwide

Updated Category News Views 259

Revolutionizing Pediatric Leukemia Treatment The Leukemia & Lymphoma Society (LLS) has embarked on an extraordinary journey with the launch of the PedAL (Pediatric Acute Leukemia) Master Clinical Trial, a trailblazing effort that marks the world's first-ever global trial focused on menin inhibitors for treating pediatric leukemia. This initiative is part of LLS's broader...

Continue Reading
Aflac Partners with Workday to Enhance Employee Benefits Experience

Updated Category News Views 196

Aflac's Collaboration with Workday for Enhanced Wellness Solutions Aflac, a prominent provider of supplemental insurance in the U.S., has entered into a partnership with Workday Wellness aimed at revolutionizing employee benefit offerings. This strategic relationship empowers employers to provide a more personalized experience for their workforce, ultimately aimed at...

Continue Reading